EUVIMEDEUVIMED entdecken
Crossref

Decipherment of disulfidptosis-related mutation profile, chemosensitivity, and prognosis in diffuse large B-cell lymphoma

Juanjuan Shang, Bingyu Liu, Xiaoli Zhou, Xiaosheng Fang, Shunfeng Hu, Xin Wang, Xiangxiang Zhou

Journal of Molecular Medicine · 2025

DOI: 10.1007/s00109-025-02571-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Medicine, 2025. Verfasst von Juanjuan Shang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Shandong Provincial Hospital, Shandong University, No.324, Jingwu Road, Jinan, 250021, Shandong, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Mutation, Drug Resistance, Neoplasm. Die Arbeit nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation, Translational Research Grant of NCRCH, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, of which 35-40% suffers recurrence after standard chemotherapy treatment. Disulfidptosis is a novel mode of cell death, which has been found to be associated with tumor environment and prognosis in several tumors. Here, we applied transcriptome profile data of 30 types of tumors, somatic mutation data, and scRNA-seq data of DLBCL patients for analysis. Disulfidptosis-related genes (DRGs) expression was found to be widely dysregulated across different tumors, and most DRGs displayed obviously high expression in DLBCL. DRGs mutations were correlated to prognosis and chemosensitivity in DLBCL. Molecular docking analysis found the potential binding of some anti-tumor drugs and proteins encoded by mutated DRGs. Besides, scRNA-seq analysis revealed the discrepancy of DRGs expression pattern and biological pathways in diverse cell clusters. Differentially expressed genes (DEGs) between disulfidptosis-related clusters were mainly enriched in immune response and metabolism related pathways. Moreover, a novel DRGs risk score was constructed and demonstrated to be accurate for prognosis prediction in both training and validation cohorts. Pan-cancer analysis showed that DRGs score displayed wider application value in different types of tumors. Chemosensitivity analysis found that there was great discrepancy of IC50 in 86 anti-tumor drugs between low- and high-DRGs score groups, such as temozolomide and sorafenib. Overall, the novel disulfidptosis-related risk score and biomarkers have the potential to provide new insights for risk stratification and treatment recommendation in DLBCL. KEY MESSAGES: The expression of disulfidptosis-related genes (DRGs) was significantly different in 30 types of tumors, and most DRGs displayed high expression in DLBCL. DRGs mutations had the potential to predict prognosis and chemosensitivity in DLBCL. Function analysis based on sequencing datasets indicated that DRGs were closely correlated to tumor immune infiltration and metabolism reprogramming. DRGs score was found to be accurate for predicting the prognosis and chemosensitivity in DLBCL. Pan-cancer analysis revealed the prognostic value of DRGs score in different tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseMutationDrug Resistance, NeoplasmHumansPrognosisGene Expression Regulation, NeoplasticTranscriptomeGene Expression ProfilingAntineoplastic AgentsBiomarkers, TumorMolecular Docking SimulationDisulfidptosis

Stichwörter der Autor:innen

ChemosensitivityDiffuse large B-cell lymphomaDisulfidptosisMutation characteristicsPrognostic signature

Substanzen

Antineoplastic AgentsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Hematology, Shandong Provincial Hospital, Shandong University, No.324, Jingwu Road, Jinan, 250021, Shandong, China.
  • Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No.324, Jingwu Road, Jinan, 250021, Shandong, China.
  • Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No.324, Jingwu Road, Jinan, 250021, Shandong, China. HuShunFeng0409@163.com.
  • Department of Hematology, Shandong Provincial Hospital, Shandong University, No.324, Jingwu Road, Jinan, 250021, Shandong, China. xinw007@126.com.
  • Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No.324, Jingwu Road, Jinan, 250021, Shandong, China. xinw007@126.com.
  • Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No.324, Jingwu Road, Jinan, 250021, Shandong, China. xiangxiangzhou@sdu.edu.cn.

Förderung

  • National Natural Science Foundation
  • Translational Research Grant of NCRCH
  • China Postdoctoral Science Foundation
  • Shandong Provincial Natural Science Foundation
  • Taishan Scholars Program of Shandong Province

Zitieren

APA

Shang, J., Liu, B., Zhou, X., Fang, X., Hu, S., Wang, X., & Zhou, X. (2025). Decipherment of disulfidptosis-related mutation profile, chemosensitivity, and prognosis in diffuse large B-cell lymphoma. Journal of Molecular Medicine. https://doi.org/10.1007/s00109-025-02571-8

Vancouver

Shang J, Liu B, Zhou X, Fang X, Hu S, Wang X, et al. Decipherment of disulfidptosis-related mutation profile, chemosensitivity, and prognosis in diffuse large B-cell lymphoma. Journal of Molecular Medicine. 2025. doi:10.1007/s00109-025-02571-8

BibTeX
@article{Shang2025,
  author = {Shang, Juanjuan and Liu, Bingyu and Zhou, Xiaoli and Fang, Xiaosheng and Hu, Shunfeng and Wang, Xin and Zhou, Xiangxiang},
  title = {Decipherment of disulfidptosis-related mutation profile, chemosensitivity, and prognosis in diffuse large B-cell lymphoma},
  journal = {Journal of Molecular Medicine},
  year = {2025},
  doi = {10.1007/s00109-025-02571-8}
}
Kostenlos starten →